Frontotemporal Dementia Management is expected to register CAGR 6% through 2033

The global Frontotemporal Dementia Management Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Frontotemporal Dementia Management registered a CAGR of 4% in the historical period 2018 to 2022.

Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal dementia management. These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop dementia.

Request a Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16489

According to the World Health Organization, around 50 million people have dementia, and there are nearly 10 million new cases every year which is anticipated to boost the industry growth. Although the cause for Frontotemporal dementia is still unknown it majorly affects the individual between the ages of 40 to 60. Frontotemporal dementia causes serious psychotic episodes and language and communication problems not limited to patients only but affects people around them.

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. Furthermore, government initiatives, increase in the number of research partnerships, presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool are boosting the market growth across North America.

Key Takeaways from the Market Study

• From 2018 to 2022, the Frontotemporal Dementia Management market grew at a CAGR of 4%.
• The global Frontotemporal Dementia Management market is expected to grow with a 6% CAGR during 2023 to 2033.
• As of 2033, the Frontotemporal Dementia Management Market is expected to reach US$ 17.91 Million
• According to the FMI analysis, hospitals account for the largest market share.
• North America is expected to possess 25% market share for the Frontotemporal Dementia Management market.
• The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period. 

“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Frontotemporal Dementia Management.” says an FMI analyst

Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16489

Market Competition

Key players in the Frontotemporal Dementia Management market are Celgene Corporation, BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Sangamo Therapeutics, Orchard Therapeutics, CRISPR Therapeutics, and DisperSol Technologies among other global players.

• In January 2021, LSP, the leading European life sciences investor, and Professor Philip Scheltens, a world-renowned dementia scientist, will launch the LSP Dementia Fund, a fund dedicated to fighting neurodegenerative diseases, in Amsterdam.
• Alzheimer’s Disease International, in collaboration with the Global Coalition on Aging (GCOA) and the Lien Foundation, will launch the third Dementia Innovation Readiness Index in 30 global cities around the world in October 2020.

Key Segments Profiled in the Frontotemporal Dementia Management Industry Survey

Drug Class Type:

• Antidepressants
  • Fluoxetine
  • Fluvoxamine
  • Sertraline
  • Paroxetine
  • Citalopram
  • Bupropion
  • Mirtazapine
• Antipsychotics
  • Olanzapine
  • Quetiapine
  • Ziprasidone
  • Aripiprazole
  • Risperidone
  • Paliperidone

End-Users:

• Hospitals
• Specialty clinics
• Others

Distribution Channel:

• Hospital Pharmacy
• Drug store
• Retail Pharmacy
• Online Pharmacy
• Others

Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16489

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs